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Abstract
The	underlying	molecular	basis	 for	neurodevelopmental	or	neuropsychiatric	disor‐
ders	is	not	known.	In	contrast,	mechanistic	understanding	of	other	brain	disorders	
including	neurodegeneration	has	advanced	considerably.	Yet,	these	do	not	approach	
the	 knowledge	 accrued	 for	 many	 cancers	 with	 precision	 therapeutics	 acting	 on	
well‐characterized	targets.	Although	the	identification	of	genes	responsible	for	neu‐
rodevelopmental	and	neuropsychiatric	disorders	remains	a	major	obstacle,	the	few	
causally	associated	genes	are	ripe	for	discovery	by	focusing	efforts	to	dissect	their	
mechanisms.	Here,	we	make	a	case	for	delving	into	mechanisms	of	the	poorly	char‐
acterized	human	KCTD	gene	family.	Varying	levels	of	evidence	support	their	roles	in	
neurocognitive	disorders	(KCTD3),	neurodevelopmental	disease	(KCTD7),	bipolar	dis‐
order	(KCTD12),	autism	and	schizophrenia	(KCTD13),	movement	disorders	(KCTD17),	
cancer	 (KCTD11),	 and	 obesity	 (KCTD15).	 Collective	 knowledge	 about	 these	 genes	
adds	enhanced	value,	 and	 critical	 insights	 into	potential	 disease	mechanisms	have	
come	from	unexpected	sources.	Translation	of	basic	research	on	the	KCTD‐related	
yeast	protein	Whi2	has	revealed	roles	in	nutrient	signaling	to	mTORC1	(KCTD11)	and	
an	autophagy‐lysosome	pathway	affecting	mitochondria	(KCTD7).	Recent	biochemi‐
cal	and	structure‐based	studies	(KCTD12,	KCTD13,	KCTD16)	reveal	mechanisms	of	
regulating	membrane	channel	activities	through	modulation	of	distinct	GTPases.	We	
explore	how	these	seemingly	varied	functions	may	be	disease	related.
K E Y W O R D S
KCTD11,	KCTD13,	KCTD7,	Neurodegeneration,	Neurodevelopmental	disorders
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1  | INTRODUC TION
Understanding	 the	 molecular	 basis	 of	 neurodevelopmental	 and	
neuropsychiatric	disorders	has	many	obstacles	 inherent	 to	disease	
complexities	and	the	lack	of	tractable	model	systems	analogous	to	
cancer	 biology.	 However,	 remarkable	 advancements	 in	 genomics	
have	 identified	 many	 potential	 candidate	 genes,	 some	 with	 addi‐
tional	compelling	evidence	for	causal	involvement	in	developmental	
and	psychiatric	brain	disorders.	Most	gene	candidates	are	relatively	
uncharacterized	 compared	 to	 the	 decades	 of	 accumulated	 knowl‐
edge	for	some	tumor	suppressors	and	oncogenes.	New	exploratory	
research	is	needed	to	decipher	the	mechanistic	details	and	organis‐
mal	 functions	of	 those	 genes	 contributing	 to	 neurodevelopmental	
and	neuropsychiatric	disorders.
A	 prime	 candidate	 for	 focused	 attention	 is	 the	 understudied	
25‐member KCTD	 gene	 family.	 Several	 human	 KCTD	 genes	 have	
emerged	in	association	with	neurodevelopmental,	neuropsychiatric,	
and	neurodegenerative	disorders.	Additional	KCTD	family	members	
are	associated	with	several	types	of	cancer	and	other	disorders,	pro‐
viding	additional	perspectives.	While	mutations	in	 individual	KCTD 
genes	 are	 found	 in	 a	 limited	 number	 of	 patients,	 collectively	 they	
provide	a	compelling	basis	to	justify	interrogation	of	their	molecular	
and	cellular	functions	to	understand	disease	mechanisms.	The	bio‐
chemical	and	biological	functions	of	KCTD	proteins	have	not	been	
deciphered,	but	progress	is	underway	(Table	1).	Some	KCTD disease 
associations	will	need	further	validation,	and	likely	many	others	are	
not	 yet	 identified.	 Deciphering	 the	 shared	 and	 distinct	 functions	
of	multiple	KCTD	family	members	will	provide	a	wealth	of	knowl‐
edge	toward	understanding	neurodevelopmental,	neuropsychiatric,	
and	 degenerative	 processes	 that	were	 previously	 impermeable	 to	
interrogation.
Human	 KCTD	 family	 proteins	 (KCTD1‐21,	 TNFAIP1,	 KCNRG,	
SHKBP1,	and	BTBD10)	can	localize	in	the	cytoplasm	or	the	nucleus,	
and	 range	 in	 size	 from	26‐kDa	KCTD5	 (234	 amino	 acids)	 to	105‐
kDa	KCTD19	 (926	amino	acids).	Mice	encode	an	additional	KCTD	
protein,	Kctd12b	(chromosome	X),	which	is	highly	similar	to	mouse	
Kctd12	(chromosome	14).	The	distinguishing	feature	of	KCTD	pro‐
teins	 is	 a	 single	 N‐terminal	 BTB/POZ	 (bric‐a‐brac,	 tramtrak,	 and	
broad	 complex/poxvirus	 zinc	 finger)	 domain,	 the	 exception	 being	
KCTD19	with	 three	 separate	BTBs	 that	may	 reflect	 tandem	gene	
amplification	 (Figure	 1).1	 BLAST	 searches	 readily	 reveal	 that	 the	
BTB	domains	of	KCTD	family	proteins	are	most	similar	in	amino	acid	
sequence	to	the	T1/BTB	domains	that	mediate	tetramerization	of	
voltage‐gated	potassium	channel	subunits	to	form	functional	chan‐
nels.1,2	This	sequence	similarity	to	Kv	channels	explains	how	KCTDs	
acquired	 their	 official	 name	 (potassium	 channel	 tetramerization	
domain).	However,	KCTD	family	proteins	lack	predicted	transmem‐
brane domains.3
An	unusual	feature	of	this	gene	family	is	their	diversity	outside	
the	BTB	domain.	Except	within	subgroups	of	closely	related	family	
members,	KCTD	proteins	 lack	obvious	 sequence	similarity	 in	 their	
highly	 variable	C‐terminal	 regions.1	 This	 feature	 is	 consistent	with	
their	proposed	roles	as	adaptor	molecules	that	use	their	C‐termini	to	
bind	and	recruit	diverse	cellular	proteins	destined	for	degradation.	In	
this	model,	KCTDs	are	responsible	for	selecting	protein	substrates	
for	ubiquitination	by	cullin‐RING	ubiquitin	 ligases	 (CRLs)	 that	bind	
to	the	BTB	domains	of	KCTD	proteins.2,4,5	Thus,	disrupted	proteo‐
stasis	 required	 for	 the	 delicate	 balance	 between	 protein	 function	
versus	degradation	could	potentially	underlie	neurological	disorders	
now	 associated	 with	 the	 brain‐enriched	 proteins	 KCTD3,	 KCTD7,	
KCTD13,	 and	KCTD17.	 This	 proposed	 adaptor	 function	 for	KCTD	
proteins	could	potentially	underlie	the	diverse	biological	processes	
reported	for	KCTD	proteins,	including	DNA	replication	(KCTD10	and	
TNFAIP1),6‐8	transcription	inhibition	(KCTD1	and	KCTD15),9,10 reg‐
ulation	of	Rho	GTPases	in	brain	development	(KCTD13),11 suppres‐
sion	 of	 hedgehog	 signaling	 (KCTD11),12	 autophagy	 induction	 and	
amino	acid	signaling	to	mTORC1	(KCTD11),13‐15	and	more	(Table	1).	
However,	 other	KCTDs	 appear	 to	 lack	 the	 ability	 to	 bind	 cullin‐3,	
implying	 distinct	 biochemical	 mechanisms.16	 For	 example,	 several	
KCTD	family	proteins	(e.g.,	KCTD12	and	KCTD13)	may	alter	neuro‐
nal	activity	and	other	signaling	pathways	by	regulating	diverse	types	
of	GTPases	 11,17‐19.	Here,	we	convey	our	current	understanding	of	
KCTD	 protein	 structure	 and	 function	 and	 how	 this	may	 relate	 to	
disease	mechanisms,	focusing	on	a	subset	of	KCTD	family	members	
implicated	in	disorders	originating	from	the	neural	crest.
2  | STRUC TURE AND FUNC TION OF KC TD 
FAMILY PROTEINS
KCTD	family	members	likely	represent	paralogs	that	arose	by	gene	
duplication	from	a	common	ancestral	gene	followed	by	divergence,	
which	 led	 to	diversification	of	 the	 current	KCTD	protein	 family	 in	
the	animal	kingdom	(Figure	2).	Solved	structures	are	available	for	the	
N‐terminal	BTB	domain	of	several	KCTD	family	proteins	primarily	re‐
vealing	pentameric	homo‐oligomers.	This	fivefold	symmetry	appears	
to	extend	through	the	C‐terminus.1‐3,19	The	BTB	domains	of	KCTD	
proteins	also	mediate	other	protein‐protein	interactions,	leading	to	
three	main	hypotheses	for	general	KCTD	mechanisms.	The	first	of	
these	is	not	favored	currently.	Reasoning	that	KCTD‐BTB	domains	
might	directly	bind	to	their	closest	cousins,	the	T1/BTB	(tetrameriza‐
tion)	domains	of	voltage‐gated	potassium	channels,	KCTD	proteins	
could	potentially	regulate	channel	assembly	or	activity.	KCTD5	was	
tested	for	the	ability	to	bind	or	affect	the	functions	of	Kv1.2,	Kv2.1,	
Kv3.4,	and	Kv4.2	channels	but	without	success.3	In	a	second	model,	
several	KCTD	family	members	are	reported	to	 indirectly	 influence	
channel	 activity	 by	mechanisms	 not	 yet	 delineated.20‐23	However,	
recent	advancements	in	this	direction	stem	for	the	finding	that	the	
BTB	domain	of	a	different	subset	of	KCTDs	(clade	F)	interacts	with	
the	 cytoplasmic	 tail	 of	 membrane‐embedded	 GABAB	 neurotrans‐
mitter	receptors	allowing	the	KCTD	C‐terminus	to	transmit	a	signal	
that	 modulates	 channels	 in	 close	 proximity.19	 The	 third	 proposed	
biochemical	mechanisms	for	KCTD	family	proteins	potentially	apply	
more	broadly	to	the	KCTD	protein	family.	The	BTB	domain	of	many	
KCTD	family	proteins	are	reported	to	bind	to	the	cullin‐3	ubiquitin	
ligase,	potentially	serving	as	adaptor	molecules	to	recruit	substrates	
     |  889TENG ET al.
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for	 ubiquitination.5	 However,	 exactly	 how	 the	KCTD	BTB	 domain	
of	KCTD	proteins	would	fit	onto	cullin‐3	is	a	matter	of	speculation.	
Furthermore,	little	is	known	about	the	structure	or	function	of	most	
KCTD	C‐termini.
KCTD	family	proteins	were	previously	classified	into	seven	phy‐
logenetic	clades	based	on	the	amino	acid	sequences	of	the	BTB	re‐
gions	alone	or	of	the	full‐length	proteins.1	Our	analysis	based	on	the	
minimal	BTB	domains	is	 in	agreement	with	the	previous	study	and	
suggests	the	existence	of	an	additional	8th	clade	that	we	termed	H	
comprised	of	KCTD7	and	KCTD14	(Figures	1,	2).	In	addition,	based	
on	our	analysis,	we	propose	to	include	the	BTB	of	KCTD9	in	the	E	
group.	Like	the	related	tetrameric	T1/BTB	domains	of	voltage‐gated	
potassium	(Kv)	channels,	the	BTB	domains	of	KCTD10	and	KCTD13	
are	 capable	 of	 forming	 tetramers.	 However,	 the	 BTB	 domains	 of	
most	KCTD	proteins	form	pentamers	(KCTD1,	−5,	−6,	−9,	−11,	−12,	
−15,	−16,	−17)	based	on	crystal	structures,	cryo‐EM,	or	other	meth‐
ods	 (Table	1).	The	exception	 is	 the	available	structure	of	SHKBP1‐
BTB,	 which	 is	 a	 monomer.5	 The	 only	 available	 full‐length	 KCTD	
protein	structure	reveals	a	fivefold	symmetry	extending	through	the	
C‐terminus	of	KCTD5,3	consistent	with	the	pentameric	structure	of	
the	C‐terminal	H1	domain	of	KCTD12.19
BTB	domains	 are	 found	 in	 other	well‐known	proteins,	 such	 as	
Skip1,	an	adaptor	for	cullin‐1	ubiquitin	ligase	complexes,	and	KEAP1,	
which	 regulates	 localization	 of	 NRF2	 in	 a	 redox‐responsive	 man‐
ner.24	The	identification	of	BTB	domains	from	other	protein	families	
as	 cullin‐binding	partners	 by	mass	 spectrometry,	 including	 several	
KCTD	family	members,25‐27	fuels	the	search	for	biological	roles	for	
KCTD	 family	 proteins	 as	 exchangeable	 adaptors	 of	 cullin‐3‐RING	
E3	 ubiquitin	 ligase	 complexes	 (CRLs).	 In	 this	model,	 cullin‐3	 inter‐
acts	with	 the	BTB	domains	of	exchangeable	adaptor	proteins	 that	
serve	to	recruit	different	protein	substrates	for	ubiquitination	by	the	
RBX‐RING	protein	bound	to	the	C‐terminus	of	cullin‐3	(Figure	3).27,28 
Thus,	KCTD	family	proteins	could	function	like	a	multihead	screw‐
driver	 to	 recruit	 different	 cellular	 proteins	 for	 selective	 degrada‐
tion	by	the	proteasome	or	the	lysosome	to	fine‐tune	many	cellular	
processes.27
Several	 KCTD	 family	 proteins	 (KCTD2,	 −5,	 −6,	 −10,	 −11,	 −13,	
−17,	 −21,	 TNFAIP1)	 have	 been	 reported	 to	 interact	 with	 cullin‐3	
and	 to	 mediate	 ubiquitination	 and	 degradation	 of	 specific	 target	
proteins.11,12,18,29‐33	 Cullin‐3	 binding	 to	 KCTD13,	 TNFAIP1,	 and	
KCTD10	may	regulate	actin	organization	and	other	cell	functions	by	
degrading	Rho	GTPases	RhoA	or	RhoB.31,33‐35	KCTD6,	KCTD11,	and	
F I G U R E  1  The	diverse	human	KCTD	
protein	family	and	yeast	Whi2.	Line	
diagrams	of	the	25	human	KCTD	family	
proteins	and	Saccharomyces cerevisiae 
Whi2	are	drawn	to	scale,	grouped	in	
color‐coded	clades	(A‐H),	ordered	as	in	
Figure	2,	and	aligned	with	respect	to	their	
BTB	domain	(solid	rectangles).	Additional	
protein	domains	with	known	or	inferred	
structures	(KHA,	YjbI,	WD40,	H1)	and	
similarity	region	H2	are	also	represented.	
KCTD11L	starts	at	an	AUU	start	codon	
adding	39	N‐terminal	residues	(hashed	
box)	before	the	first	in‐frame	AUG	
translate	start.	Gray	line	diagrams	indicate	
proteins	not	discussed	in	detail.	Scale	bar	
indicates	protein	length	in	amino	acid	
residues
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F I G U R E  2  Phylogenetic	tree	of	isolated	BTB	domains	from	KCTD	family	homologs.	Amino	acid	sequences	of	KCTD	family	proteins	
from	human	(Homo sapiens,	HOMSA),	mouse	(Mus musculus,	MUSMU),	zebrafish	(Danio rerio,	DANRE),	Drosophila melanogaster	(DROME),	
Caenorhabditis elegans	(CAEEL),	and	three	yeast	species	(Saccharomyces cerevisiae,	SACCE;	Schizosaccharomyces pombe,	SACPO;	Candida 
albicans,	CANAL)	were	collected	from	UniProt	(release	2019_02)	or	after	searches	using	the	DELTA‐BLAST	algorithm	on	the	NCBI	website.	
Sequences	were	aligned	using	MAFFT	(version	7),	and	a	neighbor‐joining	(NJ)	analysis	was	performed	with	1000	bootstrap	replicates.	
Bootstrap	support	values	above	50	are	shown	at	each	node.	The	tree	was	rooted	using	Whi2p	from	S pombe.	Yeast	sequences	were	
represented	as	an	outgroup	(red	branches).	The	arbitrary	cluster	designations	for	groups	A‐G	were	assigned	to	match	those	reported	by	
Skoblov	et al.1	The	new	H	group	is	deduced	from	this	analysis.	Compared	to	Skoblov	et al,1	we	found	that	KCTD9	segregates	within	group	E.	
Amino	acid	sequences	(Table	S1)	and	alignment	results	(Table	S2)	for	this	analysis	are	found	in	Supporting	information
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KCTD21	can	each	assemble	with	cullin‐3	and	are	reported	to	sup‐
press	hedgehog	signaling	by	degrading	Gli	deacetylase	HDAC1.12,30 
KCTD7,	KCTD9,	 and	 SHKBP1	 are	 capable	 of	 binding	 cullin‐3,	 but	
their	 substrates	 have	 not	 yet	 been	 identified.2,5,36	 Intriguingly,	
KCTD5,	−9,	−13,	−17,	 and	SHKBP1	can	 form	5:5	heterodecameric	
complexes	 with	 cullin‐3	 based	 on	 biochemical	 experiments,	 even	
though	 their	 purified	 BTB	 domains	 may	 adopt	 geometries	 of	 te‐
tramers	 or	 monomers.2,5,37	 This	 suggests	 that	 cullin‐3	 may	 drive	
assembly	 of	 KCTD	 protein	 structures.	 Validation	 of	 this	 adaptor	
function	 by	 in	 vitro	 reconstitution	 of	 KCTD‐cullin3‐RBX‐E2	 ubiq‐
uitination	reactions	is	challenged	by	the	apparent	need	to	identify	
and	include	the	specific	target	substrate	in	these	reactions.	Detailed	
biochemistry	and	structure	determinations	are	also	needed	to	con‐
firm	the	biological	evidence	that	KCTDs	function	as	cullin‐3	adap‐
tors.	Additional	binding	partners	of	KCTD	proteins	also	have	been	
identified.	KCTD1	and	KCTD15	were	 reported	 to	bind	and	 inhibit	
the	activity	of	transcription	factor	AP‐2α.9,10	KCTD10,	KCTD13,	and	
TNFAIP1	were	reported	to	regulate	DNA	replication	by	interacting	
with	 PCNA	 (proliferating	 cell	 nuclear	 antigen).6,8	 Whether	 these	
KCTD	functions	involve	cullin‐3	or	unrelated	mechanisms	is	not	yet	
established.
3  | KC TD  GENES A SSOCIATED 
WITH NEURODE VELOPMENTAL AND 
NEUROPSYCHIATRIC DISORDERS
3.1 | KCTD7 mutations cause a severe 
neurodevelopmental disorder
Our	recent	genetic	analysis	confirms	that	mutations	in	KCTD7 cause 
a	rare	early‐onset,	autosomal	recessive	disorder	 (progressive	myo‐
clonic	 epilepsy/PME3,	 also	 called	 EPM3).13	Over	 50	 patients	with	
over	 40	 unique	 variants	 in	 KCTD7	 have	 been	 identified	 to	 date,	
though	 many	 more	 likely	 remain	 unidentified.13,38‐45	 In	 all	 cases,	
patients	 have	 homozygous	 or	 compound	 heterozygous	 mutations	
(missense,	 stop‐gain,	 frameshifts,	or	 large	deletions),	while	all	het‐
erozygous	 family	members	 are	unaffected.13	Thus	 far,	 the	highest	
density	of	patient	variants	occurs	within	the	N‐terminal	BTB	domain.	
A	cluster	of	mutations	also	occurs	in	the	last	30	residues	and	in	an	
~100‐residue	middle	 region,	both	of	unknown	function.13	Patients	
appear	to	develop	normally	and	achieve	early	childhood	milestones.	
However,	between	10	and	20	months	of	age	these	children	develop	
refractory	myoclonic	 seizures,	movement	 disorders,	 and/or	 devel‐
opmental	delays.13	This	younger	age	of	onset	with	KCTD7	mutations	
(average	16	months)	distinguishes	these	patients	from	other	types	
of	progressive	myoclonic	epilepsies	(PME).	All	patients	subsequently	
progress,	 exhibiting	 severe	 cognitive	 decline,	 motor	 deficits,	 and	
seizures.13	Most	patients	become	nonverbal	and	wheelchair‐bound	
within	2	years	of	diagnosis,	but	the	few	ambulatory	patients	now	in	
their	teens	and	early	twenties	have	diagnoses	of	autism	or	schizo‐
phrenia.	This	disorder	is	also	designated	as	neuronal	ceroid	lipofus‐
cinosis	type	14	(CLN14),	primarily	on	the	basis	of	two	patients	with	
subcellular	inclusions	and	lysosome	storage	material.36,45	However,	
most	studies	concluded	that	the	subcellular	pathologies	of	KCTD7	
patients	are	distinct	from	previously	described	CLN	pathologies	and	
other	lysosomal	storage	disorders.13,41
Persistent	 difficulties	 with	 diagnosing	 this	 disorder	 have	 been	
attributed	 to	 earlier	 onset	 ages	 than	expected	 for	PME	disorders,	
negative	 biopsy	 tests	 for	 CLN‐related	 pathologies,	 negative	 brain	
MRI	findings	(with	a	few	exceptions),	and	the	fact	that	KCTD7 was 
not	confirmed	as	a	disease	gene	until	relatively	recently.	These	chal‐
lenges	have	been	partially	overcome	by	including	KCTD7 on diagnos‐
tic	sequencing	panels	for	epilepsy.	However,	at	least	25%	of	patients	
develop	movement	 disorders	 (ataxia,	 tremors,	 dyskinesia,	 choreo‐
athetosis,	dystonia)	or	regression	of	milestones	before	the	onset	of	
seizures,	though	all	eventually	develop	myoclonic	epilepsy.	Electrical	
activity	in	the	brain	detected	by	EEG	tests	is	generally	positive,	and	
brain	 biopsies	 are	 predicted	 to	 be	diagnostic	 based	on	 the	preva‐
lence	of	lipofuscin/lysosome‐like	structures	in	patient	brain.13 One 
patient	underwent	callosotomy	with	reported	benefit.13 A number 
of	patients	with	heterozygous	KCTD7	mutations	and	some	overlap‐
ping	neurological	symptoms	have	also	been	identified,	although	any	
causal	 role	 for	KCTD7	 in	 these	 cases	 is	 unknown.13	 Undiagnosed	
bi‐allelic KCTD7	gene	mutations	have	contributed	to	the	misassign‐
ment	of	disease	symptoms	to	unrelated	events	such	as	vaccinations	
routinely	 administered	 around	 the	expected	 age	of	 disease	onset.	
In	addition,	the	gene	name	for	KCTDs	has	evoked	assumptions	that	
patients	 could	 be	 treated	 for	 a	 channelopathy,46	 though	 currently	
available	evidence	does	not	justify	this	therapeutic	approach.
Although	 the	molecular	mechanisms	 underlying	 disease	 in	 pa‐
tients	with	KCTD7	mutations	are	not	known,	research	efforts	have	
begun	to	dissect	some	biological	functions.	KCTD7	protein	expres‐
sion	 was	 reported	 in	 hippocampal	 neurons	 and	 Purkinje	 cells	 of	
mouse brain.20,41	 Expressed	 wild‐type	 KCTD7	 protein	 in	 cultured	
mouse neurons or Xenopus	oocytes	was	reported	to	hyperpolarize	
the	 resting	 cell	 membrane	 potential,	 and	 some	 patient	 mutations	
F I G U R E  3  Proposed	role	for	a	subset	of	KCTD	family	proteins	
as	adaptors	for	cullin‐3	ubiquitin	ligase	complexes	(CRLs)	
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inhibited	 the	 K+	 flux	 observed	 with	 wild‐type	 KCTD7.20,23 How 
KCTD7	might	 influence	potassium	currents	 is	 not	 known	but	may	
be	 indirect	 as	 compelling	 evidence	 of	 a	 direct	 interaction	with	K+ 
channels	is	currently	lacking.	Cerebrospinal	fluid	from	some	patients	
was	reported	to	have	higher	levels	of	glutamine	and	lower	levels	of	
glutamate,	which	was	suggested	to	result	from	impaired	regulation	
of	the	neuronal	glutamine	transporter	SAT2	by	mutant	KCTD7.23
Our	biochemical	 studies	 indicate	 that	KCTD7	protein	 interacts	
with	 cullin‐3,13,20	 raising	 the	 possibility	 that	 KCTD7	may	 serve	 as	
an	 adaptor	 for	 the	 cullin‐3	 E3	 ubiquitin	 ligase	 to	mediate	 protein	
degradation	of	 targeted	substrates.	However,	no	KCTD7‐recruited	
substrate	proteins	have	been	identified.	One	study	implied	that	the	
C‐terminus	of	KCTD7	may	be	 involved	 in	binding	 cullin‐3.36	More	
recent	 evidence	 indicates	 that	 the	 BTB‐containing	 N‐terminus	 of	
KCTD7	is	required	and	sufficient	for	cullin‐3	interactions	based	on	
co‐immunoprecipitation	 assays	 and	 subcellular	 localization	 of	 ex‐
pressed	proteins.13	Furthermore,	this	interaction	with	cullin‐3	is	par‐
tially	 impaired	by	BTB	domain	mutations	found	in	patients	(R70W,	
R84Q,	L108M).13	Thus,	a	role	for	KCTD7	in	proteostasis	could	con‐
ceivably	contribute	to	progressive	disease	by	causing	the	accumu‐
lation	 of	 undegraded	 proteins,	 correlating	 with	 the	 prevalence	 of	
abnormal	lysosome‐like	structures	observed	by	electron	microscopy	
in	neurons	of	a	patient	brain	biopsy.13	Consistent	with	 these	 find‐
ings,	 electron	microscopy	 analysis	 of	 low‐passage	 skin	 fibroblasts	
derived	from	two	additional	KCTD7	patients	exhibits	abnormal	mi‐
tochondrial	cristae	morphologies,	lipid	droplet	accumulation	around	
mitochondria,	 and	 phagolysosomes	 containing	 partially	 degraded	
material,	features	that	were	absent	from	matched	control	cells.13
One	 potential	mechanism	 to	 explain	 these	 observations	 arose	
from	 yeast	 genetic	 studies.	 Fungal	 Whi2	 protein	 sequences	 and	
metazoan	KCTD	family	sequences	share	a	homologous	BTB	domain	
(IPR011333)	with	significant	sequence	similarity	(Figures	1,	2).47	It	is	
not	known	whether	both	yeast	and	mammalian	KCTD	proteins	de‐
scended	 from	 a	 common	 ancestral	 gene	 or	whether	 they	 evolved	
as	a	result	of	BTB	domain	 insertion	 into	unrelated	ancestral	genes	
(therefore,	they	share	sequence	homology	but	are	not	referred	to	as	
homologs).	The	yeast	WHI2	gene	from	Saccharomyces cerevisiae was 
originally	discovered	when	a	spontaneous	 inactivating	mutation	 in	
WHI2	was	identified	as	the	cause	for	a	cell	growth	phenotype.48,49 
Yeast	 WHI2	 was	 later	 rediscovered	 for	 similar	 reasons,	 because	
spontaneous	WHI2	mutations	caused	cells	to	continue	growing	inap‐
propriately	after	switching	cells	to	medium	with	low	levels	of	amino	
acids.50	This	is	because	Whi2	is	required	to	suppress	TORC1	kinase,	
the	master	regulator	of	cellular	responses	to	nutrient	status.14,15,51 
Interestingly,	knockdown	of	Kctd13	in	neuro2A	cells	was	reported	to	
increase	cell	proliferation.52	Whether	KCTD13	or	KCTD7	regulates	
TORC1,	or	whether	this	involves	cullin‐3‐dependent	protein	degra‐
dation	 is	not	known.	However,	given	that	TORC1	is	well	known	to	
actively	suppress	autophagy	in	yeast	and	mammals,	it	is	not	surpris‐
ing	that	whi2	‐mutant	yeast,	which	have	sustained	TORC1	activity	in	
low	amino	acid	conditions,	fail	to	induce	autophagy.13	Interestingly,	
KCTD7	patient	fibroblasts	were	found	to	have	defective	autophagy	
induction	when	starved.13	Consistent	with	a	role	for	BTB‐containing,	
cullin‐interacting	proteins	 in	autophagy	 regulation,	 the	BTB‐kelch‐
repeat	protein	KLHL20	regulates	autophagy	by	functioning	as	a	cul‐
lin‐3	adaptor	to	degrade	the	mTORC1‐inhibited	ULK1	protein	kinase	
and	the	lipid	kinase	VPS34,	both	important	for	early	steps	of	auto‐
phagosome	formation.53	Similarly,	the	F‐box	protein	and	associated	
BTB/POZ	protein	Skp1	can	mediate	cullin‐1‐dependent	degradation	
of	VPS34	to	regulate	autophagy.54
Interestingly,	 a	 spontaneous	 whi2	 mutation	 in	 yeast	 partially	
rescues	 defective	 mitochondrial	 respiratory	 function	 (petite	 phe‐
notype)	caused	by	loss	of	the	mitochondrial	fission	factor	Fis1,	also	
conserved	in	humans.47,50	By	promoting	mitochondrial	organelle	fis‐
sion,	Fis1	is	thought	to	promote	turnover	of	mitochondria	by	gener‐
ating	small	organelles	that	can	be	engulfed	by	autophagosomes.55,56 
Perhaps	sustained	TORC1	activity	in	fis1whi2	double	mutants	helps	
compensate	for	mitochondrial	insufficiency	without	Fis1,	explaining	
why	 most	 FIS1‐deletion	 strains	 develop	 a	 secondary	WHI2	 muta‐
tion.50	While	the	role	of	Whi2	versus	Fis1	in	mitochondrial	turnover	
via	mitophagy	is	debated,57,58	the	profound	defect	in	autophagy	ob‐
served	 in	knockouts	 lacking	Whi2	 (yeast	KCTD)	provided	 the	 first	
clue	about	the	function	of	human	KCTD7	in	autophagy.	This	model	is	
consistent	with	the	prevalence	of	mitochondria	containing	defective	
cristae	membrane	structures	13	and	the	altered	branching	patterns	
of	mitochondrial	organelles	observed	in	KCTD7	patient	fibroblasts	
(Figure	4).	In	the	future,	animal	models	will	likely	be	needed	to	un‐
derstand	the	physiological	and	pathological	consequences	of	Kctd7 
deficiency	 before	 grasping	 the	 organismal	 and	 behavioral	 conse‐
quences	relevant	to	human	disease	mechanisms.
3.2 | KCTD8, KCTD12, and KCTD16 in 
neurotransmitter receptor signaling
Mouse	Kctd8,	Kctd12,	Kctd12b	(not	found	in	humans),	and	Kctd16	
belong	to	clade	F	of	the	KCTD	protein	family	(Figure	2,	Table	1)1 and 
are	 considered	 auxiliary	 subunits	 of	 the	 inhibitory	 neurotransmit‐
ter	receptor	complex	GABAB1/2	(G‐protein‐coupled	receptor/GPCR	
3	 family)	 present	 on	 both	 inhibitory	 and	 excitatory	 neurons.17,59 
Supported	by	studies	in	GABAB‐deficient	mice,	GABAB	receptor	ab‐
errations	are	implicated	in	neurodegenerative	and	neuropsychiatric	
disorders,	including	seizure	disorders,	depression,	schizophrenia,	ad‐
diction,	and	several	neurodevelopmental	disorders.59‐61	Therefore,	
disruption	of	the	auxiliary	subunits	KCTD8,	KCTD12,	and	KCTD16	
may	cause	related	conditions.	A	mutation	in	the	promoter	region	of	
human	KCTD12	was	 reported	 to	contribute	 to	bipolar	 I	disorder.62 
Similarly,	elevated	protein	levels	of	human	KCTD12	were	associated	
with	depression63	and	schizophrenia.64	Consistent	with	these	find‐
ings,	 kctd12	 ‐knockout	 mice	 exhibit	 related	 phenotypes	 including	
altered	 emotional	 behaviors	 and	 increased	 neuronal	 excitability,65 
supporting	 a	 potential	 role	 for	KCTD12	 in	 neuropsychiatric	 disor‐
ders. KCTD12	 has	also	been	 implicated	 in	 several	 cancers	not	dis‐
cussed	here.
Insights	into	the	molecular	mechanisms	involved	are	at	the	fore‐
front	of	understanding	KCTD	family	protein	 functions,	and	 recent	
structure	 determinations	 further	 advance	 the	 field	 overall.	 The	
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homologous	GABAB1	and	GABAB2	receptors	(GABBR1 and GABBR2) 
function	as	heterodimers.	GABAB1	binds	the	inhibitory	neurotrans‐
mitter	gamma‐aminobutyric	acid	 (GABA),	and	the	GABAB2	subunit	
interacts	 with	 G‐proteins	 for	 signaling.	 GABAB1/2	 receptors	 mod‐
ulate	 synaptic	 transmission	 by	 indirectly	 regulating	 specific	 Ca2+ 
and K+	 channels	 through	 trimeric	 G‐proteins.66	 KCTD8,	 KCTD12,	
and	KCTD16	can	increase	the	activation	rate	of	GABAB	responses,	
and	KCTD12	can	cause	fast	desensitization	of	GABAB	receptor	re‐
sponses.17,21,67	A	new	crystal	structure	containing	the	C‐terminus	of	
GABAB2	(amino	acid	residues	876‐913)	reveals	how	the	pentameric	
BTB	domain	of	KCTD16	enwraps	 the	 cytoplasmic	 tail	 of	 the	neu‐
rotransmitter	receptor	GABAB2.
19	The	interaction	with	KCTD16	and	
also	with	KCTD12	 is	 abolished	 by	 the	BTB	mutation	 Phe80Ala	 in	
KCTD16	 and	 Phe87Ala	 in	 KCTD12,	 further	 validating	 the	 crystal	
structure.19
The	same	study	also	connects	KCTD	proteins	with	 trimeric	G‐
protein	complexes,	providing	a	model	for	how	clade	F	KCTDs	may	
transmit	 a	 signal	 to	 regulate	 potassium	 flux	 across	 the	 cell	 mem‐
brane.	The	conserved	H1	and	H2	homology	regions	were	previously	
recognized	 in	the	C‐terminus	of	clade	F	proteins,	except	H2	 is	not	
present	in	the	shorter	KCTD12	C‐terminus	(Figure	1).21	The	KCTD12	
H1	region	was	previously	shown	to	be	responsible	for	desensitiza‐
tion	of	GABAB	receptor	responses,	whereas	H2	domains	of	KCTD8	
and	KCTD16	 have	 auto‐inhibitory	 effects	 on	 their	H1	 region.21 A 
new	crystal	structure	of	KCTD12	H1	bound	to	Gβ1γ2 reveals an H1 
pentamer	 surrounded	by	 five	Gβ1γ2 dimers.
19	 Taking	 the	 evidence	
together,	 the	proposed	model	 is	 that	a	KCTD12	pentamer	dangles	
from	the	extended	cytoplasmic	 tail	of	GABAB2,	which	 is	anchored	
in	the	cell	membrane	with	GABAB1.
19	Upon	GABAB1	receptor	stim‐
ulation,	 KCTD12	 expels	 Gα	 from	 the	 inhibited	 trimeric	 G‐protein	
complex	Gαβ1γ2,	 and	membrane‐associated	Gβ1γ2	 can	 rapidly	acti‐
vate	the	associated	GIRK	(G‐protein‐coupled	inwardly	rectifying	K+ 
channel).	Then,	rapid	deactivation/desensitization	of	GIRK	channels	
would	subsequently	occur	when	KCTD12	H1	sequesters	Gβγ away 
from	these	channels.19	A	role	for	KCTD12	in	GABAB‐Gβγ	signaling	to	
regulate	potassium	channel	activity	is	not	mutually	exclusive	with	a	
role	as	a	cullin‐3	adaptor	(e.g.,	to	degrade	Gα),	except	that	the	α2β3	
loop	of	KCTD12	is	predicted	to	interfere	with	cullin‐3	interactions.16 
Therefore,	any	congruency	between	the	cullin‐binding	KCTDs	and	
GTPase	 signaling	 KCTDs	 is	 currently	 unresolved	 but	 may	 repre‐
sent	 independent	 functions	of	 the	 same	or	different	KCTD	 family	
proteins.	However,	 it	 is	 tempting	 to	 consider	 that	 these	 functions	
could	be	present	 in	 the	 same	KCTD	protein	 to	 coordinate	 cellular	
functions.
3.3 | KCTD13 association with autism and 
schizophrenia
Recent	genetic	studies	have	revealed	copy‐number	variations	(CNV)	
in	many	genes	in	association	with	developmental	brain	disorders,	in‐
tellectual	disability,	epilepsy,	autism	spectrum	disorder,	and	schizo‐
phrenia.68 KCTD13	(also	known	as	BACURD1 or POLDIP1)	is	located	
in	the	16p11.2	locus,	which	is	known	to	contribute	to	risk	of	multi‐
ple	neuropsychiatric	disorders.	Deletions	of	16p11.2	are	associated	
with	epilepsy,	autism,	and	autism	spectrum	disorder	(ASD),69	while	
16p11.2	duplications	are	associated	with	autism	and	schizophrenia.70 
F I G U R E  4  Altered	mitochondrial	morphology	in	KCTD7	mutant	patient	fibroblasts.	Primary	passage‐matched	human	fibroblasts	from	
(A)	an	age‐matched	control	and	(B)	a	patient	with	compound	heterozygous	R84W/D106fs	mutations	in	KCTD7	were	confirmed	by	Sanger	
sequencing	and	qRT‐PCR	analysis	as	described.13	To	visualize	mitochondrial	organelles,	cells	grown	on	round	12‐mm‐diameter	glass	
coverslips	(FisherBrand)	were	fixed	(10	min	in	cold	4%	paraformaldehyde),	permeabilized	(5	min	with	0.2%	Triton	X‐100)	and	immunostained	
1	h	with	anti‐Tom20	antibody	and	Alexa	Fluor®	secondary	antibodies	(Santa	Cruz),	mounted	in	Prolong	Gold,	and	0.5	μmol/L	Z‐stack	images	
were	captured	on	a	Nikon	90i	at	40x	or	60x	magnification	using	Volocity	software	for	deconvolution.	(For	quantification,	mitochondria	
in	some	experiments	were	labeled	instead	with	100	nmol/L	Mitotracker	Red	for	15	min	prior	to	fixation.)	Double‐blinded	images	were	
converted	to	8‐bit	grayscale,	binarized	and	skeletonized	using	a	custom	ImageJ	plug‐in,	and	mitochondrial	structure	parameters	(including	
length,	size,	branching,	degree	of	clustering,	circularity)	were	quantified	using	“Analyze	Skeleton	2D/3D”	ImageJ	plug‐in	for	2‐3	independent	
experiments.	The	total	mitochondrial	network	per	cells	was	significantly	reduced	in	long‐branch	frequency	in	KCTD7	mutant	fibroblast	
compared	to	control	fibroblast.	Individual	mitochondrial	subnetworks	(skeletons)	are	rainbow	colored	according	to	total	length	(red	longest,	
blue	shortest).	Position	of	the	nucleus	in	each	cell	is	marked	by	a	gray	circle
(A)
(B)
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Interestingly,	dosage	effects	of	16p11.2	appear	to	affect	head	size	
in	humans,	with	deletions	observed	in	macrocephaly	and	duplication	
observed	in	microcephaly.70
Zebrafish	and	mouse	model	 systems	have	helped	 to	overcome	
the	 major	 challenge	 of	 dissecting	 the	 individual	 contributions	 to	
disease	of	the	many	genes	present	16p11.2	duplications/deletions.	
Zebrafish	 have	 been	 useful	 in	 other	 studies	 to	 investigate	 human	
dosage‐sensitive	genes	and	can	reflect	anatomical	phenotypes	ob‐
served	 in	 early	 human	 development.71	 Therefore,	 zebrafish	 were	
used	to	dissect	human	16p11.2,	which	encompasses	29	genes	that	
when	deleted	in	humans	can	confer	susceptibility	to	neurocognitive	
defects.52,69	Results	from	overexpression	of	each	of	these	29	genes	
individually	 in	zebrafish	embryos	 identified	a	single	gene,	KCTD13,	
capable	 of	 inducing	 microcephaly,	 a	 phenotype	 of	 patients	 with	
16p11.2	 duplication.52	 Conversely,	 transient	 suppression	 of	 the	
orthologous	Zebrafish	kctd13	 locus	resulted	 in	the	reciprocal	mac‐
rocephaly	phenotype.52,72,73	The	 importance	of	Kctd13	 for	cellular	
proliferation	was	confirmed	in	developing	mouse	brains.	In	contrast	
to	these	studies,	others	failed	to	detect	 increased	brain	size	or	 in‐
creased	neurogenesis	 in	mice	or	zebrafish	when	 the	entire	Kctd13 
locus	was	deleted	in	zebrafish	or	mice.11	The	discrepancy	between	
both	 lines	 of	 data	may	 be	 due	 to	 different	 compensation	mecha‐
nisms	between	knockdown	approaches	 and	genetic	deletion,	 pos‐
sible	phenotypic	differences	between	Kctd13	knockdown	in	only	a	
subset	of	neural	progenitors	versus	complete	genetic	deletion	of	the	
Kctd13 locus,	or	alternatively,	contributions	from	other	genes	located	
in	16p11.2.
Other	studies	demonstrate	that	in	mouse	models,	Kctd13	epistat‐
ically	affects	anatomical	phenotypes	in	combination	with	Mvp	(major	
vault	protein)	or	Lat (linker for activation of T cells),	genes,	which	are	
also	 located	 in	16p11.2	 loci52,74.	However,	 recent	studies	reported	
no	robust	abnormalities	in	brain	structure	of	mice	with	genetic	abla‐
tion	of	Kctd13,	and	instead	observed	sex‐specific	differences	in	brain	
volume	of	double	heterozygous	mice	lacking	one	copy	of	Kctd13 and 
one	copy	of	either	Lat or Mvp,	also	located	in	16p11.2.75	These	re‐
sults	suggest	that	altered	dosage	of	Kctd13,	and	Mvp or Lat	may	have	
epistatic	effects	on	brain	size.
KCTD13	has	been	reported	to	function	as	a	cullin‐3	adaptor	for	
ubiquitination	 and	 degradation	 of	 RhoA,	 a	 small	 GTPase	 protein	
that	is	a	key	regulator	of	actin	cytoskeleton	and	plays	critical	roles	
in	 neuronal	 development	 and	 synaptic	 function.33,76	 Consistently,	
genetic	deletion	of	the	entire	Kctd13	gene	has	resulted	in	increased	
RhoA	expression,	the	loss	of	dendritic	spines	and	reduced	synaptic	
activity	in	the	CA1	region	of	the	hippocampus.11,76	Reduced	synaptic	
transmission	 is	 normalized	by	 pharmacological	 inhibition	 of	RhoA.	
These	results	suggest	that	KCTD13	may	recruit	RhoA	for	modulating	
its	turnover	via	the	cullin‐3	ubiquitin	ligase,	thereby	regulating	syn‐
aptic	 function,	consistent	with	spatiotemporal	network	analysis	of	
brain subregions.34	This	Kctd13‐knockout	mouse	(entire	Kctd13 gene 
deleted)	 lacked	 detectable	 memory	 deficits.11	 However,	 an	 inde‐
pendently	constructed	Kctd13‐deficient	mouse	with	an	out‐of‐frame	
exon	2	deletion	(expected	to	fully	ablate	Kctd13)	exhibited	deficits	
in	 short‐term	 recognition	memory,	 but	 lacked	 detectable	 changes	
in	 expression	 levels	 of	 RhoA,	 the	 candidate	 KCTD13‐cullin	 target	
substrate.75	However,	RNA‐seq	analyses	of	gene	expression	profiles	
from	the	cortex	and	hippocampus	of	Kctd13	‐deficient	(exon	2‐de‐
leted)	mice	revealed	altered	signaling	pathways	critical	for	neurode‐
velopment,	including	synaptic	formation,	and	both	knockout	mouse	
lines	exhibited	reduced	spine	density	in	the	hippocampus.11,75	Thus,	
further	studies	are	required	to	understand	the	mechanistic	complex‐
ities	by	which	Kctd13	copy	number	modulates	brain	development	
beyond	RhoA	signaling.	It	would	also	be	of	great	interest	to	investi‐
gate	how	multiple	genes	in	16p11.2	loci	 interplay	to	regulate	brain	
development	and	contribute	 to	neurodevelopmental	abnormalities	
and	psychiatric	disorders	such	as	schizophrenia	and	autism.
3.4 | KCTD17 in myoclonus‐dystonia
Myoclonus‐dystonia	syndrome	(MDS)	 is	a	rare	movement	disorder	
characterized	by	nonepileptic	spontaneous	muscle	contractions	and	
dystonia.77	Approximately	25‐50%	of	myoclonus‐dystonia	cases	are	
caused	 by	 autosomal	 dominant	mutations	 in	 the	SGCE	 gene,	 cod‐
ing	 for	ε‐sarcoglycan.78	Thus,	 there	are	additional	genetic	variants	
responsible	for	this	disease,	and	several	candidate	genes	have	been	
identified,	some	of	which	have	been	confirmed.79,80 KCTD17	variant	
c.434G	>	A,	p.Arg145His	was	identified	by	combining	genome‐wide	
linkage	analysis	and	whole‐exome	sequencing	of	a	large	British	pedi‐
gree	and	of	a	second	German	family	with	autosomal	dominant	myo‐
clonus‐dystonia	but	lacking	SGCE	gene	mutations.79	Additional	tests	
confirmed	the	lack	of	a	common	ancestor	between	these	two	fami‐
lies. KCTD17	 (c.434G	 >	A,	 p.Arg145His)	was	 the	 only	 segregating	
variant	among	seven	candidates	from	affected	myoclonus‐dystonia	
patients	in	the	British	family.79	Very	recently,	two	additional	KCTD17 
mutations	affecting	the	same	splice	acceptor	site	(c.508‐2A	>	T	and	
c.508‐1G	 >	 T)	 were	 identified	 in	 two	 independent	 studies.81,82	 It	
has	been	pointed	out	 that	 the	clinical	 features	of	 the	KCTD17 pa‐
tients	 are	 phenotypically	 distinguishable	 from	MDS	 due	 to	 SGCE 
mutations.80	However,	 the	evidence	 is	 reasonably	 compelling	 that	
KCTD17	mutations	are	 responsible	 for	a	subset	of	myoclonus‐dys‐
tonia.	Although	autosomal	dominant	KCTD17	mutations	cause	 less	
severe	disease	than	bi‐allelic	KCTD7	mutations	discussed	in	section	
3.1,	both	KCTD7 and KCTD17	disorders	have	some	overlapping	clini‐
cal	 features	 including	 difficulty	 swallowing,	 impaired	 verbal	 skills,	
cognitive	 impairment,	 difficulties	 with	 fine	 motor	 skills,	 and	 their	
disease	is	progressive,	unlike	SGCE	mutations.
The	biological	 functions	of	KCTD17	are	not	 yet	 clear.	KCTD17 
mRNA	was	shown	to	be	broadly	expressed	across	the	brain	but	par‐
ticularly	 in	the	putamen,	consistent	with	dystonia	being	caused	by	
dysfunction	 of	 basal	 ganglia	 circuits.79	 Fibroblasts	 derived	 from	 a	
KCTD17	patient	 (p.Arg145His)	exhibit	defective	ER	calcium	signal‐
ing,	which	is	suggested	to	underlie	myoclonus‐dystonia	linked	to	mu‐
tations	in	other	genes	(e.g., HPCA,	CACNA1A,	ANO3).79,83
KCTD17	has	also	been	reported	to	function	as	an	adaptor	of	the	
cullin‐3	ubiquitin	 ligase	 to	mediate	ubiquitination	 and	degradation	
of	 trichoplein,	which	 is	a	negative	 regulator	of	ciliogenesis.32	Both	
neurons	and	astrocytes	contain	a	primary	cilium,	and	ciliogenesis	has	
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been	reported	to	play	an	important	role	in	brain	development.84	This	
raises	the	possibility	that	defective	ciliogenesis	caused	by	KCTD17 
mutations	contributes	to	the	pathology	of	myoclonus‐dystonia.
The	BTB	domain	 of	mammalian	KCTD17	 is	most	 similar	 in	 se‐
quence	 to	 KCTD2,	 KCTD5,	 and	 KCTD9,	 which	 together	 consti‐
tute	 clade	E	 (Figure	2,	Table	1).1	Mammalian	KCTD2,	KCTD5,	 and	
KCTD17	are	homologs	of	Drosophila	Insomniac	protein	(Inc),	a	regu‐
lator	of	sleep	homeostasis	and	synaptic	function	in	flies.85 Insomniac 
was	 reported	 to	 be	 a	 substrate	 adaptor	 of	Drosophila	 cullin‐3	 and	
may	regulate	turnover	of	yet	unknown	neuronal	targets	to	regulate	
sleep	 and	 synaptic	 functions.85	 Both	 insomniac	 and	 its	 mamma‐
lian	homologs	are	expressed	in	the	nervous	system	and	localize	to	
synapses.86	Mouse	KCTD2,	KCTD5,	and	KCTD17	can	each	hetero‐
multimerize	with	Drosophila	 Insomniac	and	also	bind	 to	Drosophila 
cullin‐3	 in	 vitro,	 suggesting	 conserved	 functions.86	 Although	 only	
mouse	KCTD2	and	KCTD5,	but	not	KCTD17,	were	able	to	rescue	the	
sleep	phenotype	in	flies	lacking	Insomniac,	the	inability	of	KCTD17	
to	restore	sleep	in	 insomniac	mutant	flies	was	suggested	to	be	due	
to	its	low	expression	in	transgenic	flies.86 Drosophila Insomniac and 
cullin‐3	also	regulate	dopaminergic	signaling.85	Dysfunction	of	dopa‐
minergic	pathways	has	been	associated	with	myoclonus‐dystonia.87 
Currently,	the	molecular	links	between	KCTD17‐cullin3‐dependent	
protein	degradation,	synaptic	function,	dopaminergic	signaling,	and	
pathology	of	myoclonus‐dystonia	remain	unclear.
3.5 | KCTD3 in neurocognitive disease
KCTD3,	also	known	as	NY‐REN‐45,	has	been	identified	in	several	ge‐
nome‐wide	screens	for	disease	variants.	A	bi‐allelic	frameshift	muta‐
tion	in	KCTD3	(c.1036_1073del,	p.P346Tfs*4)	was	first	identified	in	
one	family	by	whole	exon	sequencing	of	143	multiplex	families	with	
neurocognitive	disorders.88	This	same	KCTD3	mutation	was	later	re‐
ported	 in	 a	 2.5‐year‐old	 patient.89	Homozygous	KCTD3	mutations	
were	identified	in	three	additional	families,	one	harboring	the	same	
frameshift	mutation	 (c.1036_1073del,	 p.P346Tfs*4),	 and	 the	other	
two	harboring	a	missense	mutation	(c.166C	>	T,	p.Arg56*).90 KCTD3 
patients	exhibit	global	developmental	delay,	seizures,	and	cerebellar	
hypoplasia.88,90
The	 biological	 function	 of	 KCTD3	 protein	 has	 not	 been	 in‐
vestigated	 in‐depth,	but	one	 study	provides	 some	evidence	 that	
links	KCTD3	with	 the	nervous	system.	Mouse	Kctd3	was	 identi‐
fied	 as	 a	 binding	 partner	 of	 Hcn3	 (hyperpolarization‐activated	
cyclic	 nucleotide‐gated	 channel)	 in	 a	 yeast	 two‐hybrid	 screen.91 
Immunoprecipitation	 from	 mouse	 brain	 lysates	 suggests	 that	
Kctd3	specifically	binds	to	Hcn3,	but	not	to	the	other	Hcn	chan‐
nels	 (Hcn1,	 Hcn2,	 and	 Hcn4).91	 Immunostaining	 confirmed	 that	
Kctd3	and	Hcn3	colocalize	 in	 several	brain	 regions	 including	hy‐
pothalamus,	midbrain	and	cerebellum.	Kctd3	increases	Hcn3	cur‐
rent	density	by	promoting	trafficking	of	Hcn3	protein	to	the	cell	
membrane.91	Human	HCN	channels	 are	widely	 expressed	 in	 the	
brain	and	are	reported	to	control	cellular	excitability	and	synaptic	
transmission.92,93	Whether	KCTD3	also	 regulates	 these	neuronal	
functions	is	not	yet	known.
4  | RELE VANCE OF OTHER KC TD FAMILY 
MEMBERS TO THE NERVOUS SYSTEM
4.1 | KCTD11 in cancer
KCTD11	has	been	implicated	as	a	tumor	suppressor	in	several	can‐
cers,	most	notably	 in	medulloblastoma,	a	primary	brain	tumor	of	
childhood.94	 Suggested	 mechanisms	 include	 KCTD11‐mediated	
suppression	 of	 the	 hedgehog	 signaling	 pathway	 by	 interacting	
with	cullin‐3	via	 the	BTB	domain	of	KCTD11,	while	 the	KCTD11	
C‐terminus	recruits	the	Gli	deacetylase	HDAC1	for	degradation.12 
KCTD11	 is	 located	 on	 17p13.1	 near	 TP53. In an in vivo mouse 
screen	 to	 test	 the	 effect	 of	 haploinsufficiency	 of	 TP53‐linked	
genes,	mouse	Kctd11	was	identified	as	a	tumor	suppressor	gene.95 
However,	neither	of	these	findings	has	been	confirmed	by	follow‐
up	investigations.
Until	 very	 recently,	 human	 KCTD11	 was	 annotated	 in	 the	
NCBI	 and	 UniProt	 databases	 as	 a	 232	 amino	 acid	 protein	 with	 a	
truncated	BTB	domain	 (currently	 annotated	 at	NCBI	 as	KCTD11s,	
NP_001002914).	 However,	 coding	 sequencings	 for	 the	 missing	
N‐terminal	 segment	 of	 the	 BTB	 domain	 are	 present	 in‐frame	 im‐
mediately	preceding	 the	most	5‐prime	ATG	start	of	 translation.	 In	
vitro	studies	suggest	 that	KCTD11	 is	 translated	 from	an	upstream	
non‐AUG	(AUU)	start	codon	(which	may	occur	more	commonly	than	
appreciated),	 adding	 39	 amino	 acids	 to	 the	 N‐terminus	 of	 human	
KCTD11.96	NCBI	recently	revised	the	annotation	of	human	KCTD11	
as	a	271	amino	acid	protein	including	a	full	BTB	domain	(KCTD11l,	
NP_001350571).	A	recent	study	showed	that	yeast	Whi2	sharing	a	
BTB	domain	homologous	to	that	of	human	KCTD	proteins	is	capable	
of	inhibiting	TORC1	under	low	amino	acid	conditions.14	Remarkably,	
human	 KCTD11	 but	 not	 other	 KCTD	 proteins	 tested	 (KCTD7,	
KCTD8,	KCTD11,	KCTD12,	and	KCTD16)	could	suppress	TORC1	ac‐
tivity	when	expressed	in	whi2	‐deficient	yeast	and	in	mammalian	cell	
lines	under	 low	amino	acid	 conditions.14	 Furthermore,	 knockdown	
of	KCTD11	 in	HEK293	cells	confirmed	that	KCTD11	 is	 required	to	
suppress	 mTORC1	 during	 amino	 acid	 deprivation.14	 The	 detailed	
molecular	mechanism	of	 how	KCTD11	 regulates	mTORC1	activity	
is	still	unknown.	One	speculation	is	that	there	is	crosstalk	between	
mTORC1	and	the	hedgehog	signaling	pathways	through	KCTD11	in	
cancer.
4.2 | KCTD15 in neural crest formation and obesity
Genome‐wide	association	studies	 (GWAS)	have	 identified	KCTD15 
variants	 in	association	with	 increased	risk	of	obesity.97,98	Although	
the	detailed	molecular	mechanisms	are	not	known,	several	 lines	of	
evidence	 suggest	 a	 potential	 role	 for	 KCTD15	 in	 obesity	 through	
inhibition	of	Wnt	 signaling.	KCTD15	was	 reported	 to	control/limit	
neural	crest	formation	in	zebrafish	and	frog	embryos	by	attenuating	
the	Wnt‐β‐catenin	signaling	pathway,	as	overexpression	of	KCTD15 
decreased	neural	crest	formation	while	KCTD15	knockdown	caused	
neural	crest	size	to	increase.99	Follow‐up	studies	carried	out	by	the	
same	group	showed	that	 in	zebrafish	embryos	and	 in	human	cells,	
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KCTD15	directly	inhibits	the	transcription	factor	AP‐2α,	a	target	of	
Wnt	signaling,	consistent	with	a	role	for	KCTD15	in	neural	crest	de‐
velopment.10	The	proposed	mechanism	is	that	KCTD15	binds	to	the	
proline‐rich	 activation	 domain	 of	AP‐2α	 to	 prevent	 transcriptional	
activation	by	AP‐2α	and	that	SUMO	modification	in	the	C‐terminus	
of	zebrafish	Kctd15	on	Lys252	(human	K278)	inhibits	the	ability	of	
KCTD15	 to	 suppress	 transcription	 and	 inhibit	 neural	 crest	 forma‐
tion.10,100	Given	that	mesenchymal	stem	cells	and	some	adipocytes	
are	derived	from	the	neural	crest,101	and	that	AP‐2	regulates	the	ex‐
pression	of	genes	 important	 for	adipogenesis,	such	as	C/EBPα and 
IRS‐	1,102,103	it	is	conceivable	that	KCTD15	may	regulate	adipogen‐
esis	by	regulating	AP‐2	transcription	activity	 in	neural	crest	during	
development.
5  | PERSPEC TIVES
Several	human	KCTD	 family	genes	are	expressed	predominantly	 in	
the	brain.	Genetic	alternations	in	KCTD	family	members	have	been	
associated	 with	 neurodevelopmental	 disorders,	 epilepsy,	 autism,	
schizophrenia,	 movement	 disorders,	 obesity,	 and	 several	 cancers,	
but	little	is	understood	about	the	biological	functions	of	KCTD	fam‐
ily	proteins	(Table	1).	The	original	expectation	that	BTB	domains	of	
KCTD	family	members	might	directly	partner	with	their	nearest	ho‐
mologs,	the	T1/BTB	domains	of	voltage‐gated	potassium	channels,	
currently	lacks	confirmation.	However,	new	evidence	supports	roles	
for	KCTDs	 in	signaling	pathways	 to	 indirectly	modulate	potassium	
channel	activity.	KCTDs	appear	 to	be	 involved	 in	other	processes,	
including	nutrient	 sensing	 and	 autophagy,	 based	on	work	 in	 yeast	
showing	that	the	yeast	KCTD‐like	protein	Whi2	interacts	with	yeast	
phosphatases	Psr1/Psr2	to	regulate	TORC1	activity.14	The	plethora	
of	effects	of	KCTD	family	proteins	may	reflect	an	adaptor	function	
of	KCTDs	that	recruits	substrates	for	ubiquitination	by	cullin‐3	and	
subsequent	degradation,	though	evidence	also	supports	additional	
mechanisms.	 The	highly	 variable	C‐terminal	 regions	of	KCTD	pro‐
teins	could	potentially	 reflect	 their	 roles	 in	 recruiting	diverse	 sub‐
strates	for	cullin‐3‐mediated	ubiquitination	and	degradation,	though	
this	 is	only	one	possibility.	A	binding	 site	of	 the	heterotrimeric	G‐
protein	subunits	Gβγ	has	been	mapped	to	the	C‐terminus	of	KCTD12	
and	KCTD16.	Though	it	is	not	known	whether	this	interaction	serves	
only	to	desensitize	the	G‐protein	coupled	inwardly	rectifying	potas‐
sium	channel	GIRK	or	whether	KCTD‐mediated	protein	turnover	or	
other	 functions	 are	 involved.	Defects	 in	 ubiquitination‐dependent	
protein	function	and/or	GTPase	modulated	ion	flux	may	underlie	the	
neurodevelopmental	and	neuropsychiatric	disorders	associated	with	
mutations	affecting	KCTD	family	proteins.	In	addition,	more	animal	
models	are	needed	to	understand	pathophysiological	roles	of	KCTDs	
before	comprehending	the	detailed	mechanisms	of	human	disease.
Difficulties	 in	 diagnosing	 children	 with	 rare	 disease	 muta‐
tions	 in	 KCTD	 proteins	 have	 contributed	 to	 the	 misassignment	
of	symptoms	to	other	causes.	The	early‐onset	age	for	autism	and	
several	other	KCTD‐associated	disorders	coincide	with	the	timing	
of	 childhood	 vaccinations.	 Consequently,	 patient	 narratives	 and	
social	media	 indicate	 that	 these	 families	 spent	 years	without	 an	
explanation	for	their	child's	illness.	Patients	with	undiagnosed	dis‐
ease	mutations	 seek	 explanations	 from	 circumstantial	 evidence.	
For	example,	until	2012	there	was	only	a	single	publication	impli‐
cating	KCTD7	mutations	in	disease.38	Similarly,	a	separate	cohort	
of	patients	with	encephalopathies	attributed	to	vaccine	reactions	
were	 instead	 due	 to	 de	 novo	 mutations	 in	 SCN1A.104,105	 Thus,	
from	a	policy	perspective	as	well	as	from	a	therapeutic	perspec‐
tive,	new	knowledge	about	KCTD	 family	protein	 functions	 is	ur‐
gently	needed.
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